A Clinician's Guide to the Treatment of Endometriosis with Elagolix.
J Womens Health (Larchmt). 2021 Apr; 30(4):569-578.JW

Abstract

Pain associated with endometriosis is a considerable burden for women, permeating all aspects of their lives, from their ability to perform daily activities to their quality of life. Although there are many options for endometriosis-associated pain management, they are often limited by insufficient efficacy, inconvenient routes of administration, and/or intolerable side effects. Elagolix, a nonpeptide, small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist, is the first new oral therapy to be approved for the treatment of endometriosis-associated pain in the United States in more than a decade. Modulation of estradiol with elagolix is dose dependent and ranges from partial to full suppression. Clinical evidence has shown that elagolix at both approved doses (150 mg once daily and 200 mg twice daily) is effective for reducing symptoms of pelvic pain (dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia), improving quality of life, and decreasing use of rescue analgesics (nonsteroidal anti-inflammatory drugs and/or opioids). The availability of two dosing options allows for individualization of treatment based on baseline clinical factors and response to therapy. Elagolix is well tolerated, with less pronounced hypoestrogenic effects compared with GnRH agonists. This review provides an overview of elagolix, highlighting currently available treatment options and the application of this new treatment for women with endometriosis-associated pain.

Links

PMC Free PDF

Authors+Show Affiliations

Leyland N

Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada.

Estes SJ

Department of Obstetrics and Gynecology, Penn State Health, Hershey, Pennsylvania, USA.

Lessey BA

Wake Forest Health, Center for Fertility, Endocrine and Menopause, Winston-Salem, North Carolina, USA.

Advincula AP

Department of Obstetrics and Gynecology, Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York, USA.

Taylor HS

Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut, USA.

MeSH

EndometriosisFemaleHumansHydrocarbons, FluorinatedPyrimidinesQuality of LifeReceptors, LHRH

Pub Type(s)

Journal Article

Research Support, Non-U.S. Gov't

Review

Language

eng

PubMed ID

32975461

Citation

Leyland, Nicholas, et al. "A Clinician's Guide to the Treatment of Endometriosis With Elagolix." Journal of Women's Health (2002), vol. 30, no. 4, 2021, pp. 569-578.

Leyland N, Estes SJ, Lessey BA, et al. A Clinician's Guide to the Treatment of Endometriosis with Elagolix. J Womens Health (Larchmt). 2021;30(4):569-578.

Leyland, N., Estes, S. J., Lessey, B. A., Advincula, A. P., & Taylor, H. S. (2021). A Clinician's Guide to the Treatment of Endometriosis with Elagolix. Journal of Women's Health (2002), 30(4), 569-578. https://doi.org/10.1089/jwh.2019.8096

Leyland N, et al. A Clinician's Guide to the Treatment of Endometriosis With Elagolix. J Womens Health (Larchmt). 2021;30(4):569-578. PubMed PMID: 32975461.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - A Clinician's Guide to the Treatment of Endometriosis with Elagolix. AU - Leyland,Nicholas, AU - Estes,Stephanie J, AU - Lessey,Bruce A, AU - Advincula,Arnold P, AU - Taylor,Hugh S, Y1 - 2020/09/22/ PY - 2020/9/26/pubmed PY - 2021/5/21/medline PY - 2020/9/25/entrez KW - GnRH receptor antagonist KW - dysmenorrhea KW - elagolix KW - endometriosis KW - pelvic pain SP - 569 EP - 578 JF - Journal of women's health (2002) JO - J Womens Health (Larchmt) VL - 30 IS - 4 N2 - Pain associated with endometriosis is a considerable burden for women, permeating all aspects of their lives, from their ability to perform daily activities to their quality of life. Although there are many options for endometriosis-associated pain management, they are often limited by insufficient efficacy, inconvenient routes of administration, and/or intolerable side effects. Elagolix, a nonpeptide, small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist, is the first new oral therapy to be approved for the treatment of endometriosis-associated pain in the United States in more than a decade. Modulation of estradiol with elagolix is dose dependent and ranges from partial to full suppression. Clinical evidence has shown that elagolix at both approved doses (150 mg once daily and 200 mg twice daily) is effective for reducing symptoms of pelvic pain (dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia), improving quality of life, and decreasing use of rescue analgesics (nonsteroidal anti-inflammatory drugs and/or opioids). The availability of two dosing options allows for individualization of treatment based on baseline clinical factors and response to therapy. Elagolix is well tolerated, with less pronounced hypoestrogenic effects compared with GnRH agonists. This review provides an overview of elagolix, highlighting currently available treatment options and the application of this new treatment for women with endometriosis-associated pain. SN - 1931-843X UR - https://www.unboundmedicine.com/medline/citation/32975461/full_citation DB - PRIME DP - Unbound Medicine ER -

Tags

A Clinician's Guide to the Treatment of Endometriosis with Elagolix.J Womens Health (Larchmt). 2021 Apr; 30(4):569-578.JW